|
|
TABLE 3.
Tests for HCV infectiona
|
|
| Test and
type |
Description |
Application(s) |
Comments
|
|
| Anti-HCV |
EIA and
supplemental assay (i.e., recombinant immunoblot assay
[RIBA]) |
Indicates past or present infection but does not
differentiate between acute, chronic, or resolved infection; all
positive EIA results should be verified by a supplemental
assay |
Sensitivity 97%; EIA alone has low positive predictive
value in low-prevalence populations |
| HCV RNA |
| Qualitative
testsb,c |
Reverse transcriptase PCR
(RT-PCR) amplification of HCV RNA by in-house or commercial assays
(e.g., Amplicor HCV) |
Detects presence of circulating HCV RNA; for
monitoring patients on antiviral therapy |
Detects virus as early as
1-2 weeks after exposure; detection of HCV RNA during course of
infection may be intermittent (a single negative RT-PCR result is not
conclusive); false-positive and false-negative results might occur
|
| Quantitative testsb,c |
RT-PCR
amplification of HCV RNA by in-house or commercial assays (e.g.,
Amplicor HCV Monitor); branched-chain DNA assays (e.g., Quantiplex HCV
RNA Assay) |
Determines concentration of HCV RNA; may be useful for
assessing the likelihood of response to antiviral therapy |
Less
sensitive than qualitative RT-PCR; should not be used to exclude the
diagnosis of HCV infection or to determine treatment endpoint
|
| Genotypingb,c |
Several
methodologies available (e.g., hybridization, sequencing) |
Groups
isolates of HCV based on genetic differences into six genotypes and
>90 subtypes; with new therapies, length of treatment may vary based
on genotype |
Genotype 1 (subtypes 1a and 1b) most common in United
States and associated with lower response to antiviral therapy
|
| Serotypingb |
EIA based on
immunoreactivity to synthetic peptides (e.g., Murex HCV Serotyping 1-6 Assay) |
No clinical utility |
Cannot distinguish between subtypes;
dual infections often observed |
|
|
a
Adapted from reference
64a.
|
|
b
Currently not FDA approved; lack
standardization.
|
c
Samples require special handling (e.g., serum
must be separated within 2 to 4 h of collection and stored frozen
[ 20 or 70°C]; samples should be shipped on dry ice).
|